Company Profile: Done Global Inc.

Background

Overview

Done Global Inc., established in 2019, is a San Francisco-based telehealth provider specializing in the diagnosis and treatment of Attention Deficit Hyperactivity Disorder (ADHD) and other chronic psychiatric conditions. The company offers virtual consultations, connecting patients with clinicians who may prescribe medications such as Adderall, Ritalin (methylphenidate), and Vyvanse (lisdexamfetamine). Additionally, Done integrates digital therapies and support systems to provide comprehensive mental health care to its patients.

Mission and Vision

Done's mission is to empower individuals living with ADHD to reach their fullest potential by providing accessible and affordable psychiatric care. The company envisions a world where high-quality mental health services are readily available to those in need, leveraging technology to bridge gaps in traditional healthcare delivery.

Key Strategic Focus

Core Objectives

Done focuses on delivering personalized online treatment for ADHD, aiming to make psychiatric care more accessible and affordable. The company emphasizes a member-first mentality, meeting patients where their needs are and providing high-quality care in an accessible and affordable manner.

Areas of Specialization

The company's primary specialization lies in ADHD treatment, offering services such as online ADHD testing, medication prescriptions, and ongoing care management. Done also provides digital therapies and support systems to enhance patient outcomes.

Key Technologies Utilized

Done leverages telemedicine platforms to facilitate virtual consultations, enabling patients to connect with clinicians remotely. The company integrates digital health tools to streamline the diagnosis and treatment process, ensuring efficient and effective care delivery.

Primary Markets Targeted

Done primarily targets individuals diagnosed with or suspecting they have ADHD, offering services across the United States. The company aims to reach patients seeking convenient and affordable mental health care solutions.

Financials and Funding

Funding History

Done has secured funding from notable investors, including Craft Ventures, F7 Ventures, and Offline Ventures. The company closed its last funding round on September 23, 2020, from a Seed round.

Revenue

Estimates of Done's annual revenue vary:

$114.8 million per year, with an estimated revenue per employee of $337,500.

$4.1 million, with 50 employees.

$1.7 million in 2024.

Intended Utilization of Capital

The capital raised has been intended to expand Done's telehealth services, enhance technological infrastructure, and increase patient outreach to provide accessible ADHD treatment nationwide.

Pipeline Development

Key Services

Done offers a range of services, including:

Online ADHD Testing: Initial self-assessment followed by appointments with specialized medical providers for official diagnosis.

ADHD Medication Prescription: Prescriptions for stimulant and non-stimulant medications after thorough assessment by licensed clinicians.

Ongoing ADHD Care: Online visits, medication refills, and 24/7 access to clinicians for continuous management.

Development Stages and Timelines

As a telehealth service provider, Done's development focuses on expanding service offerings and enhancing platform capabilities. Specific timelines for new service rollouts are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

Done utilizes a proprietary telemedicine platform that facilitates virtual consultations, patient assessments, and treatment management, ensuring a seamless and user-friendly experience.

Significant Scientific Methods

The company employs evidence-based clinical protocols for ADHD diagnosis and treatment, integrating digital tools to monitor patient progress and adjust treatment plans accordingly.

Leadership Team

Key Executives

Ruthia He: Founder and Chief Executive Officer. Prior to founding Done, He was a product designer at Facebook. She has been instrumental in shaping the company's vision and strategic direction.

David Brody: Clinical President of Done Health P.C. Brody oversees the clinical operations, ensuring the delivery of high-quality psychiatric care.

Leadership Changes

In June 2024, the U.S. Department of Justice charged Ruthia He and David Brody with distributing controlled substances via telemedicine, healthcare fraud, and obstruction of justice. These charges have led to significant leadership upheavals within the company.

Competitor Profile

Market Insights and Dynamics

The telehealth industry has experienced rapid growth, particularly in mental health services. However, companies like Done have faced increased scrutiny over prescribing practices and quality of care, leading to regulatory challenges and shifts in market dynamics.

Competitor Analysis

Key competitors in the telehealth ADHD treatment space include:

Cerebral: Offers virtual therapy and medication management for various mental health conditions. Faced similar scrutiny over prescribing practices.

AbleTo: Provides virtual behavioral health therapy and coaching programs.

PocDoc: Focuses on at-home diagnostic testing and telehealth consultations.

BetterNight: Specializes in sleep therapy and related telehealth services.

Strategic Collaborations and Partnerships

Done has collaborated with a network of pharmacies to streamline medication management and ensure timely access to prescribed treatments. However, in 2022, major pharmacy chains, including CVS and Walmart, ceased filling prescriptions from Done clinicians due to concerns over prescribing practices.

Operational Insights

Strategic Considerations

Done's rapid growth and focus on accessibility positioned it as a significant player in the telehealth ADHD treatment market. However, regulatory challenges and legal issues have impacted its operations and market position.

Competitive Advantages

Initially, Done's competitive advantages included its user-friendly telemedicine platform, affordability, and convenience. Recent legal challenges have affected these advantages, necessitating strategic reassessment.

Strategic Opportunities and Future Directions

Given the legal challenges faced by Done, the company may need to focus on regulatory compliance, rebuilding trust with patients and partners, and enhancing clinical protocols to ensure sustainable operations in the future.